Search Results - Lars Bastholt

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy by Lærke K. Tolstrup, Lars Bastholt, Ann-Dorthe Zwisler, Karin B. Dieperink, Helle Pappot

    Published in Journal of Patient-Reported Outcomes (2019-03-01)
    Get full text
    Article


  2. 2

    Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab by Anders H. Kverneland, Christian Enevold, Marco Donia, Lars Bastholt, Inge Marie Svane, Claus H. Nielsen

    Published in OncoImmunology (2018-05-01)
    Get full text
    Article


  3. 3

    The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial by Lærke K. Tolstrup, Lars Bastholt, Karin B. Dieperink, Sören Möller, Ann-Dorthe Zwisler, Helle Pappot

    Published in Journal of Patient-Reported Outcomes (2020-10-01)
    Get full text
    Article


  4. 4

    Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility by Jonas K. Oddershede, Ida K. Meklenborg, Lars Bastholt, Louise M. Guldbrandt, Henrik Schmidt, Rasmus B. Friis

    Published in Acta Oncologica (2025-04-01)
    Get full text
    Article


  5. 5

    Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II st... by Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, Patrick Schöffski, Yann Godbert, Patrice Rodien, Barbara Jarzab, Domenico Salvatore, Sylvie Zanetta, Jaume Capdevila, Lars Bastholt, Christelle De La Fouchardiere, Yassine Lalami, Stéphane Bardet, Frank Cornélis, Marek Dedecjus, Thera Links, Ward Sents, Martin Schlumberger, D. Laura Locati, Katie Newbold

    Published in Frontiers in Endocrinology (2024-06-01)
    Get full text
    Article


  6. 6

    Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma by Dirk Schadendorf, Ralf Gutzmer, Caroline Robert, Celeste Lebbe, Gabriella Liszkay, Inge Marie Svane, Omid Hamid, Paolo Antonio Ascierto, Catriona McNeil, Claus Garbe, Michele Maio, Vanna Chiarion-Sileni, Luc Thomas, Andrzej Mackiewicz, Carmen Loquai, Ana Arance, Piotr Rutkowski, Laurent Mortier, Lars Bastholt, Brigitte Dreno, Marta Nyakas, Jean-Jacques Grob, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Joanna Pikiel, Fareeda Hosein, Burcin Simsek, Michele Del Vecchio

    Published in Journal for ImmunoTherapy of Cancer (2020-05-01)
    Get full text
    Article


Search Tools: